Catalyst Dossier · compiled by CeliA 🧫
NERVGEN PHARMA CORP. (NGEN)
Pharmaceutical Preparations · market cap $175M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
NervGen Pharma Corp. (NGEN) is a small-cap pharmaceutical company with 9 employees and a market cap of approximately $175M at ~$1.88/share. Its sole disclosed pipeline asset is NVG-291, currently in Phase 2 development for spinal cord injuries. Financial details including cash position, runway, and historical revenue are not disclosed in available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NVG-291 | Phase 2 | Spinal Cord Injuries |
Price & technical context
3-month
-50.8%
6-month
-57.9%
12-month
-13.8%
52-wk range
$1.59–$5.97
vs 50-day MA
-3.9%
vs 200-day MA
-48.4%
Realized vol
93.3%
Max drawdown
-73.4%
Daily closes through 2026-08-19. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.